NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
NOVO NORDISK A S
Financials through fiscal 2025, year ended Dec 31, 2025
$38.42−0.41 (-1.06%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
81.0%−2.5 pts over 5 years
Operating margin
41.3%−1.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.4% | +20.4% | +19.5% | +11.1% | |
| Gross profit | +1.8% | +19.0% | +18.7% | +10.6% | |
| Operating income | -0.5% | +19.5% | +18.7% | +9.9% | |
| EPS, diluted | +1.8% | +23.5% | +20.7% | +13.0% | |
| Free cash flow | -20.1% | -4.0% | +5.0% | +6.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 1.26 | 0.94 | 0.80 | |
| Net debt to EBITDA | – | – | 0.82× | |
| Interest coverage | 66.7× | 20.6× | 18.8× | |
| Inventory turnover | – | 1.2× | 1.3× | |
| Capex to revenue | 6.3% | 4.6% | 19.5% | |
| Diluted shares | 5.07B | 4.68B | 4.45B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Novo Nordisk A S generated 482.87B DKK from operations and spent 421.11B DKK on capital expenditure, dividends and share buybacks. 36% of that went back into the business.
Generated
482.87B DKK
Used
421.11B DKK
Capital expenditure151.59B DKK36%Dividends174.49B DKK41%Share buybacks95.03B DKK23%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero119.10B DKK
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income119.10B DKK vs –
- Less leverageLong-term debt to assets fell19.3% → 21.9%
- Better liquidityCurrent ratio rose0.74 → 0.80
- No dilutionShare count did not rise4.46B → 4.45B
- Gross margin improvedGross margin up on the prior year84.67% → 80.98%
- More efficientAsset turnover rose0.92 → 0.66